
Harmony Biosciences: Stock Dips After FDA Rejects Pitolisant Application for Treatment of Sleep Disorder
FDA Issues Refusal to File for Harmony Biosciences’ Pitolisant for Idiopathic Hypersomnia On Wednesday, Harmony Biosciences Holdings, Inc. (HRMY) received a setback in its quest to bring pitolisant, an investigational therapy for excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH), to the market. The U.S. Food and Drug Administration (FDA) issued a…